Search by conditions:


Protocol Description Phase
16-510 A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD009, A Humanized B7-H3 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients with Unresectable or Metastatic B7-H3-Expressing Neoplasms and Neoplasms whose Vasculature Expresses B7-H3  (View details on Phase I
16-534 A Phase 1, Open-Label, Dose Escalation Study of Intravenous Administration of Single Agent BTP-114 in Patients with Advanced Solid Tumors and a Known Deleterious BRCA or DNA Repair Mutation  (View details on Phase I
16-493 A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration- Resistant Prostate Cancer and DNA-Repair Anomalies  (View details on Phase II
18-117 A Phase 2 Study of PCM-075 in Combination with Abiraterone and Prednisone in Subjects with Metastatic Castration-Resistant Prostate Cancer  (View details on Phase II
18-289 A Phase I, First-in-Human, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral TP-0184 Administered Daily for 21 Days to Patients with Advanced Solid Tumors  (View details on Phase I
16-244 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy  (View details on Phase III
14-375 A Single-arm Open Label Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate Cancer  (View details on Phase II
16-212 An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors  (View details on Phase II
08-207 Circulating Tumor Cell Analysis in Patients with Localized Prostate Cancer Undergoing Prostatectomy  (View details on N/A
16-150 Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers  (View details on Phase I
17-687 Phase 1b/2 Study To Evaluate Safety And Anti Tumor Activity Of Avelumab In Combination With The Poly(Adenosine Diphosphate [Adp]-Ribose) Polymerase (Parp) Inhibitor Talazoparib In Patients With Locally Advanced Or Metastatic Solid Tumors  (View details on Phase II
11-497 Phase III Randomized Clinical Trial of Proton Therapy vs IMRT for Low or Low-intermediate Risk Prostate Cancer  (View details on Phase III
12 clinical trials listed

Back to Top